Endothelial cells are a known source of hematopoietic growthenhancing factors, including platelet-derived growth factor (PDGF). In addition, endothelium interacts directly with plasma lipoproteins which have been shown to modulate hematopoiesis. To determine the relationship of these properties, we measured the release of an erythroid growth-enhancing factor from bovine endothelial cells under lipid-loaded and control conditions. Human bone marrow cells cultured under serum-free conditions form more erythroid, granulocyte/macrophage, and mixed hematopoietic colonies when supplemented with endothelial cell-conditioned medium (ECCM) than do controls (P < 0.05). The activity is expressed over a wide range of erythropoietin, lymphocyte-conditioned medium (LCM), recombinant human interleukin-3, and colony-stimulating factor (CSF) concentrations, and is related to ECCM dose. In contrast, enhancing activity in ECCM prepared with 0-400 ,ug/ml acetylated low density lipoproteins (AcLDL) or native LDL is diminished to 0% in a dose-dependent fashion (relative to ECCM from unexposed cells or from cells incubated with very low density lipoproteins, P < 0.05). Upon dilution, medium prepared from cells incubated with LDL shows a rightward shift in the dose-response curve for erythroid colony formation, while that prepared from AcLDL loaded cells demonstrates a downward shift, indicating that the inhibitory activities are kinetically distinct. Delipidation of ECCM prior to addition to marrow culture removes the inhibitory action of native LDL (P < 0.05) but not that of AcLDL (P > 0.10). Immunochemical analysis suggests that the erythropoietic activity in ECCM is unrelated to that of PDGF, recombinant human CSF, and erythroid burst-promoting activity (BPA) present in LCM. This conclusion is supported by Northern blot analysis of endothelial cells using a cDNA probe for the v-sis homologue of the PDGF , chain and by immunoprecipitation of metabolically labeled PDGF. The relative amounts of c-sis transcripts and of secreted PDGF were simi-
Introduction
The vascular endothelium is an integral component of human bone marrow stroma that is located in close apposition to developing hematopoietic cells (1) . Endothelial cells have been implicated as a source of hematopoietic growth-enhancing molecules, including colony-stimulating activity (2, 3) and a factor(s) that promotes the formation of erythroid and mixed granulocyte-erythroid-monocyte-megakaryocyte (GEMM)' colonies in vitro (4, 5) . In addition, endothelial cells give rise to several mitogens for smooth muscle cells, 3T3 cells, fibroblasts, and glial cells (6) (7) (8) (9) that are collectively termed endothelial cell-derived growth factors (EDGFs). Recently, DiCorleto and Bowen-Pope (10) have shown that one ofthese factors derived from bovine aortic endothelial cells is a platelet-derived growth factor (PDGF)-like protein. They have also suggested that production of this factor which binds to the receptor for PDGF may be suppressed by intracellular cholesterol accumulation induced by exposure to oxidized acetylated low density lipoproteins (AcLDL) (1 1, 12) .
We have previously shown that PDGF prepared from human platelets is a determinant of optimal erythroid progenitor cell proliferation in marrow culture (13) . Rather than stimulating erythroid progenitors directly, PDGF is believed to augment erythropoiesis in vitro via an effect on mesenchymal cells, which in turn enhance colony formation (14) . In this communication, we have probed the relationship of endothelial cell-derived erythroid enhancing factors and PDGF-like proteins by examining whether or not exposure of endothelium to AcLDL alters the secretion of erythroid growth factors that are assayable under serum-free conditions. We have found that AcLDL inhibit the expression of an erythroid enhancing molecule in a fashion that is kinetically distinct from the inhibitory action of native LDL and is the result of im-paired growth factor release from endothelial cells into liquid culture medium.
Methods
Cholesterol loading of endothelial cells. Passaged bovine aortic endothelial cells, designated BAEC, were obtained by collagenase digestion and maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 10% heat-inactivated calf serum, L-glutamine (200 mM), penicillin (25,000 U/ml), and streptomycin (25,000 gg/ml) (Gibco, Grand Island, NY). Passaged human endothelial cells (PHEC) were isolated by standard techniques and maintained in the presence of endothelial growth factor (Malloy Laboratories, Springfield, VA) and heparin according to the methods of Thornton et al. (15) . Cells were grown on tissue culture plastic (100-mm Costar dishes) and used in experiments before 25TH subculture from primary isolation for BAEC, and before 6T subculture for PHEC. Endothelial cell-conditioned medium (ECCM) was prepared by washing cell monolayers with serum-free Hanks' balanced salt solution several times and incubating cells in DME as described except that the serum concentration was reduced to 0.4% lipoprotein-deficient serum (or, for biochemical analysis, to 0% serum), and that native or acetylated lipids were added as described below. At the conclusion of 24 or 48 h, the medium was harvested, centrifuged at 1,000 g for 5 min, and stored at -20'C until use.
Human low density lipoproteins (LDL; density, 1.019-1.063) and very low density lipoproteins (VLDL; density, 0.94-1.006) were isolated by heparin-manganese precipitation from recovered plasma (American Red Cross, Needham, MA) as described previously (16) , followed by assessment of purity by double radial immunodiffusion. The amino groups on the LDL were acetylated by reaction with acetic anhydride following the method of Fraenkel-Conrat (17) , and the changed electrophoretic mobility of the AcLDL was verified on agarose gels (18). Cholesterol measurements were made on sonicated isopropanol extracts of cell monolayers by fluorometric assay (19 (20) . They contained Iscove's modified Dulbecco's medium (IMDM) (Gibco), highly purified, delipidated human serum albumin, saturated ferric chloride/transferrin, and 0-4 U/ml sheep step III erythropoietin (Connaught Laboratories, Ontario, Canada) or recombinant human erythropoietin (70,000-80,000 U/mg, Amgen Biologicals, Thousand Oaks, CA). Test plates contained 10% vol/vol nonmitogenic base medium, ECCM (with or without LDL, VLDL, or AcLDL), and/or lymphocyte-conditioned medium (LCM) (22) . In some cases, 10% purified human or porcine PDGF, human colonystimulating factor (CSF; Hyclone, Logan, UT), recombinant human granulocyte-macrophage (GM)-CSF (Genetics Institute, Cambridge, MA), or recombinant human IL-3 (rHSIL-3; Genetics Institute) was also added at concentrations indicated in the figures and tables. Cultures were maintained at 370C, 5% CO2 in humidified air. Colonies consisting of 8-49 benzidine-positive cells appearing after 7 d were scored as colony-forming unit, erythroid (CFU-E)-derived colonies. Burst-forming unit, erythroid (BFU-E)-and CFU-GEMM-derived colonies were scored on day 12 of incubation. Erythroid bursts consisted of 2 50 nucleated cells that were benzidine positive and mixed hematopoietic colonies consisted of morphologically identifiable granulocytes, erythroblasts (benzidine-positive), macrophages, and megakaryocytes. Granulocyte/macrophage (G/M) colonies consisted ofaggregates containing 2 Characterization ofECCM activity. To determine whether the enhancing activity in ECCM competes with stimulatory activity expressed by PDGF, ECCM was added to cultures containing 1-100 ng of highly purified human PDGF (kindly provided by Dr. Thomas Deuel, Washington University Medical Center, St. Louis, MO) or electrophoretically pure porcine PDGF (23; Bethesda Research Labs, Gaithersburg, MD)/ml. In addition, ECCM was incubated at 100°C for 10 min and residual activity was assayed in culture. Finally, ECCM was tested in cultures containing 66 Mg L-asparagine, 3-mercapto-1,2-propanediol/ml, a thiol-containing compound whose reducing action results in inactivation of erythroid enhancing activity expressed by PDGF (13) .
ECCM was also tested for enhancing activity in cultures containing LCM, which is known to contain erythroid burst-promoting activity (BPA), rHSIL-3, or recombinant GM-CSF. To further investigate the relatedness of ECCM enhancing activity to BPA and recombinant GM-CSF, attempts were made to immunoprecipitate the growth factor, as described below. For preparative SDS gel electrophoresis, serum-free bovine ECCM prepared with insulin, transferrin, and selenous acid (ITS, Collaborative Research, Lexington, MA) was concentrated 10-fold by pressure filtration (Amicon Corp.), and dialyzed against PBS, pH 7.2, for 4 d, 4°C. The sample was heated to 70°C for 10 min in the presence of 1% SDS and 20 mM dithiothreitol and electrophoresed on 10% polyacrylamide gels according to the method of Laemmli (24) . The gel was sliced into 1-cm sections and electroluted for 48 h, using the method of Hunkapiller et al. (25) . For culture purposes, the eluted samples were supplemented with penicillin and streptomycin and extensively dialyzed as above. Residual SDS in the form of a precipitated salt was removed by centrifugation at 15,600 g for 30 s in a Eppendorf microfuge. 100 Ml of supernatants was added to culture (10%, vol/vol) and eluted activity was assayed under serum-free conditions. brane antibody employed cross-reacts with and neutralizes BPA but does not neutralize naturally released human GM-CSF (Hyclone) and does not remove erythropoietic or granulopoietic activity from recombinant human GM-CSF (Genetics Institute) (26a). In additional experiments, 300 M1 of ECCM diluted as indicated in Table III was incubated overnight, 4VC, with 300 yd of sheep anti-human recombinant GM-CSF antiserum (Genetics Institute) in an amount capable of neutralizing 100 U of recombinant human GM-CSF (27) . Antiserum was also incubated with 5-20 U ofrecombinant GM-CSF or 0. Cytoplasmic RNA extraction, sis transcript analysis, and PDGF immunoprecipitation. RNA was prepared following the method ofFavaloro et al. (28) . Lipid-loaded and control cell monolayers of BAEC, PHEC, human osteosarcoma cells, and human dermal fibroblasts were harvested by trypsin digestion. They were then lysed in buffer containing 0.14 M NaCl, i.5 mM MgCl2, 10 mM Tris-Cl, pH 8.6, 0.5% NP-40, and 10 mM vanadyl ribonucleoside complex (Bethesda Research Labs). Nuclei were removed by centrifugation over a 24% sucrose cushion and the resulting supernatant was digested with proteinase K (100 ug/ml) (Bethesda Research Labs). The digested cytoplasmic lysate was extracted with chloroform and phenol (1:1) and precipitated by adding 1.25 vol of isopropyl alcohol and stored at -20°C.
The RNA precipitate was pelleted, washed with 70% ethanol, dried, and hydrated in distilled water. Its mass was determined spectrophotometrically at 260 nm. The integrity of RNA was determined by ethidium bromide staining of electrophoresed 1% agarose gels containing 0.4 M morpholinopropanesulfonic acid and 0.5% formaldehyde (29) .
After photography, the gels were blotted onto nitrocellulose membrane (NC) (Schleicher & Schuell, Inc., Keene, NH) by standard techniques (30) , baked for 1 h, 80°C, in a vacuum oven, and stored at -20°C. Dot blots were made following the protocol of White and Bancroft (31) . Briefly, aliquots of RNA were denatured by heating in 40% formaldehyde at 65°C for 15 min, serially diluted and blotted onto nitrocellulose under suction.
RNA transcripts specific for the (3 chain of PDGF were identified by hybridization of the immobilized RNA with a nick-translated 32p_ labeled v-sis DNA probe (obtained from Drs. Aronson and Robbins of the National Cancer Institute) following standard techniques (29, 30) . NC membranes were incubated in a prehybridization buffer containing 0.2% bovine serum albumin (Sigma Chemical Co., St. Louis, MO), 0.2% ficoll (type 400, Pharmacia Fine Chemicals), 0.2% polyvinyl pyrrolidone (Sigma Chemical Co.), 5 X SSC (1 X = 0.15 M NaCl, 0.01 5 M Na Citrate), 50 mM Na P04, pH 6.5, 1% SDS, 50% deionized formamide (Bethesda Research Labs), and a 1:4 addition of 50% Dextran sulfate (Sigma Chemical Co.) at 0.5 ml/cm2 NC membrane at 42°C for 4-18 h. The radiolabeled DNA probe was denatured by boiling and added to prehybridization buffer (0.04 ml/cm2). The hybridization reaction proceeded at 42°C for 18 h after which the membranes were exhaustively washed at high stringency (low salt and 65°C) to remove nonspecific radioactivity. After the final wash, NC membranes were exposed to Kodak XAR-5 film (Kodak) at -70°C.
For immunoprecipitation, cells were grown to confluence after which growth medium was withdrawn and replaced by DME lacking cysteine (Gibco) supplemented with [35S]cysteine (0.50 mCi/ml) (Amersham Corp.). Medium was conditioned for 18 h, collected, centrifuged (500 g for 5 min) to remove cell debris, shell frozen in an acetone/dry ice bath, and lyophilized. This material was rehydrated and dialyzed against immunoprecipitation buffer containing protease inhibitors and precipitated with rabbit anti-human PDGF IgG. The immunoprecipitates were then boiled in SDS and applied to a polyacrylamide gel for electrophoresis, following standard techniques (24 Fig. 1 , day 7 and 12 erythroid colonies were also increased by undiluted ECCM (P < 0.05). A similar effect was observed on CFU-GEMM and CFU-G/M proliferation (see Table I ). The erythroid-enhancing activity peaked or reached a plateau at concentrations greater than lx, and was gradually reduced at concentrations of lx and -x (see Fig. 1 ). No erythroid colonies formed in the absence of added erythropoietin, and no mixed colonies formed in the absence of added LCM (see Table I ). The erythropoietic effect of ECCM was present at all erythropoietin, LCM, and CSF concentrations tested (Fig. 2) . Not only the number but also the size of erythroid colonies and bursts was increased by ECCM. Likewise, 1 X ECCM increased the number of G/M colonies formed with 5, 10, or 20 U/ml recombinant GM-CSF, and the number of mixed hematopoietic colonies formed with 0.5, 1.0, 2.5, and 5.0 U/ml recombinant human IL-3 by two-to threefold at each growth factor concentration (P < 0.05 for each).
In order to assess the nature of bone marrow cells that are targeted by erythroid enhancing activity, ECCM was assayed in cultures seeded at cell concentrations approaching threshold for the system. Both day 7 and 12 colony numbers were increased in cultures containing 2 X 1 cells/ml (data not shown). Additionally, ECCM enhanced erythroid colony formation in cultures of marrow mononuclear cells depleted of accessory monocytes and lymphocytes (Table II) . Next, anti-CSF antiserum was used in an effort to immunoprecipitate the active ECCM factor(s). As shown in Table  III Cholesterol effects on growth-enhancing activity. We next prepared marrow cultures with ECCM made by exposure to endothelial cells which had been incubated with lipoproteincontaining medium. Fig. 3 shows that CFU-E-enhancing activity is suppressed by native LDL and AcLDL in a dose-related fashion to levels at or below controls containing nonmitogenic base medium. Furthermore, colony formation in the presence of base medium containing these lipoproteins (400 ,ug/ml) was reduced below that in the presence ofbase medium alone, although the magnitude of the inhibitory effect was diminished relative to that observed with ECCM (see Fig. 3 ). In contrast, exposure ofendothelial cells to VLDL did not alter the expression of enhancing activity. Similar lipid effects were observed in assays for CFU-GEMM proliferation (see Table I ) and BFU-E proliferation (data not shown). Therefore, both native and acetylated forms of LDL suppress hematopoietic growth factor expression.
To determine whether the effects of native and acetylated forms of LDL are distinguishable by direct addition of lipidcontaining ECCM to culture, we examined the effects of various dilutions of ECCM prepared with 0-400 ,ug of lipoproteins/ml. Fig. 4 shows that inhibitory lipid activity is partially reversed by dilution of ECCM. Medium prepared with 100 or 160 ,g of AcLDL/ml stimulates colony formation at dilutions of up to kx, whereas suppression by 400 ug of AcLDL/ml persists at dilutions of up to 4x (see Fig. 4b ). In contrast, both stimulatory and inhibitory activities are promptly ablated at a dilution of -x for all concentrations of native LDL (see Fig. 4  a) fractions prepared in the absence of lipid (see Fig. 6 ). In contrast, neither supranates nor infranates of AcLDL-loaded cells express enhancing activity (see Fig. 6 (Fig. 6 ).
Since lipids are present in the supranate fraction alone, our findings may be explained by a direct suppressive effect of native and AcLDL on erythroid colony formation plus an additional suppressive effect of AcLDL on the production or release of erythroid stimulatory molecules from endothelial cells. The latter finding is reminiscent ofthe reported effects of AcLDL on release of PDGF-like proteins by endothelial cells (11, 12 [ECCM] 0e
Interactions of ECCM activity with other erythroid enhancers. We next assessed the possibility that the active endothelial cell molecule is PDGF. To determine whether these factors compete for the same biological effect, we assayed ECCM in marrow cultures with and without highly purified PDGF. The data in Fig. 2 b indicate that ECCM augments erythroid colony formation at each PDGF concentration. Similar results were observed in the plateau portion of the PDGF dose-response curve, suggesting that the erythroid enhancer in ECCM is additive with (and therefore biologically distinct from) PDGF. Since bioactive molecules in ECCM may share antigens with erythroid BPA, we attempted to remove the active factor from ECCM by immunoabsorption with antimembrane IgG that removes soluble BPA from LCM (26) . However, enhancing activity remained unchanged (P > 0.10) after absorption with 100 or 200 jug IgG/ml, followed by precipitation with staphylococcal Protein A (preabsorption burst stimulation, 160±8%; postabsorption burst stimulation, 148±12 and 154±10% for 100 and 200 ,gg/ml, respectively). Together with our finding that stimulation by ECCM is present at a saturating LCM concentration (Fig. 2 a) , the data suggest that the active moiety in ECCM is not identical to erythroid BPA. Influence of lipid loading on ,8-chain PDGF gene expression. Next, we investigated whether endothelial cells maintained under these various conditions of exposure to lipoproteins differentially express mRNA for the ,8-chain of PDGF. PDGF 13 chain is encoded by the homologue (c-sis) of the simian virus transforming gene (v-sis) (33) . Fig. 7 shows that a sis mRNA transcript is present in cytoplasmic RNA extracted from endothelial cells. This mRNA species was found in both lipid-loaded and control PHEC as well as in BAEC, and it was demonstrated in control human osteosarcoma cells but not in human dermal fibroblasts (Fig. 7) .
To determine whether cholesterol loading has an effect on PDGF message, cDNA probe for v-sis homologue of PDGF was used to determine message levels in PHEC before and after incubation with AcLDL. As displayed in Fig. 8 control level of 33±3 to 164±10 and 157±6 CFU-E-derived colonies/2 X 105 cells, respectively). Moreover, ECCM was inactivated by heat exposure using conditions under which PDGF erythroid growth stimulatory activity is known to be retained (13) (see Table IV ).
To determine the approximate size of the active erythroid enhancing molecules in ECCM, preparative SDS gel electrophoresis was performed. Fig. 10 shows that maximum colonystimulating activity was eluted in two of the gel slices containing molecules with reduced molecular masses of 75,000-105,000 daltons (slice 3) and 105,000-160,000 daltons (slice 2).
Discussion
As a structural component of nuclear, mitochondrial, and plasma membranes, cholesterol is critical to maintaining mechanical stability ofall eukaryotic cells (34) . Recently, we have suggested that endogenous cholesterol synthesis may be important for maintenance of proliferating human erythroid progenitor cells in serum-free culture (20) . Blockage of cholesterol synthesis in mammalian cells in vitro results in profound effects on a variety of cell functions, including differentiation and cell fusion (35) (36) (37) (38) . While most cultured cells synthesize cholesterol even in the presence of serum (39, 40) , the role played by exogenous cholesterol as a nutrient for cell growth is also well recognized (41) . Here, we have studied the influence of exogenous cholesterol on the release of growth-enhancing molecules from human and bovine endothelial cells. We show that when cultured endothelium is incubated with acetylated LDL as a source of exogenous cholesterol, hematopoietic growth factor release is markedly impaired. Suppression is not explained by an effect of LDL per se since delipidation of ECCM before addition to hematopoietic culture does not reverse the inhibitory action of acetylated LDL (Figs. 5 and 6 ). Furthermore, stimulatory and inhibitory activities are readily separated by dilution of ECCM prepared with native LDL but not of that prepared with acetylated LDL (see Fig. 4 ). Our findings suggest that cholesterol loading of endothelial cells with acetylated but not with native LDL interferes with release of the growth-enhancing factor. The biochemical mechanism Next, the enhancing factor behaves as a non-PDGF molecule. Its sensitivity to heat (100°C, 10 min) and its resistance to thiol-containing compounds suggest that it is biochemically distinct from PDGF. Unlike PDGF, it comigrates with molecules having a molecular mass of 75,000-160,000 daltons on preparative SDS gels. Results of studies in coculture with highly purified PDGF suggest that its activity is additive with that of human and porcine PDGF. Moreover, although acetylated LDL impair the release of the factor (1 1, 12) , levels of endothelial cell mRNA for the $-chain of PDGF as well as secretion of immunologically precipitable PDGF are similar Growth Factor Release Impairment by Acetylated Lipoproteins 841 '1 under lipid-loaded and control conditions (42; see also Figs. 8 and 9). Together, the data strongly suggest that the hematopoietic EDGF is a non-PDGF molecule. On the one hand, candidates for the active moiety include novel as well as previously described growth factors, including GM-CSF-like molecules which may act as multilineage hematopoietins (43) and which have been recently described to be produced by cultured human endothelium using a cDNA probe to human GM-CSF (44) . Stimulation of erythroid burst formation by a crude CSF preparation (Fig. 2 b) is consistent with this possibility. On the other hand, lack of immunologic cross-reactivity with a human recombinant GM-CSF preparation suggests that a unique erythropoietic factor may be present. Purification of the active component(s) in ECCM is in progress.
Our observation that native LDL suppress hematopoietic colony formation concurs with previous reports showing that this lipoprotein fraction of serum is inhibitory to hematopoietic progenitor proliferation (45) (46) (47) . Although the cellular mechanism for LDL suppression is unknown, our approach may be applicable to the study of this phenomenon since serum LDL are known to inhibit a number of lymphocyte responses, including generation of an immune response and lymphoproliferation both in vitro and in vivo (37-49). Because hematopoietic growth-promoting molecules are released from peripheral blood mononuclear cells (25, (50) (51) (52) , it is possible that LDL alter interactions among various lymphocyte and/or monocyte populations and other cell types, including hematopoietic progenitor cells and endothelial cells. Such interactions have been reported to be important in the generation of multilineage and granulocyte/macrophage colony-stimulating activities from cultured endothelial cells (53) (54) (55) (56) (57) . Our findings underscore the importance of carefully defining the medium in which endothelial cells are maintained. For example, detection of growth factor release by endothelial cells in the absence of monocyte-derived products may require serum-free hematopoietic culture conditions. In this respect, the in vitro effects of endothelial cell-derived enhancing factors may be similar to those of classic hormones and PDGF (58) .
In summary, our results suggest that endothelial cells are a source of hematopoietic growth-enhancing molecules whose release is abrogated by cholesterol loading using AcLDL as a vehicle. These molecules, which appear to be distinct from other well characterized hematopoietic growth factors, may be directly mitogenic for progenitor cells or may replace growth factors for nonhematopoietic cells that are normally present in the marrow microenvironment. Studies employing a purified EDGF molecule will be useful in defining the precise mechanism by which acetylated lipoproteins interfere with growth factor release.
